GlassScriptPhysician profile
Riley J Larner
NPI 1194485904
$2,577.14
in general payments reported to CMS, 2019-2025
18 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $125 · 2024: $572 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.14 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.63 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $382.52 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Madrigal Pharmaceuticals | $350.11 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $297.96 | 2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $296.72 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $185.99 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $178.39 | 2023-2025 | |
| Novo Nordisk INC | $88.68 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.57 | 2025 | Xifaxan |
| Lilly USA, LLC | $68.29 | 2024 | Jardiance, Mounjaro |
| Aimmune Therapeutics, INC. | $65.93 | 2025 | Zenpep |
| Exact Sciences Corporation | $47.89 | 2024-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $43.30 | 2025 | Dupixent |
| Abiomed | $23.54 | 2024 | |
| Vivus LLC | $19.01 | 2025 | Qsymia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $14.80 | 2025 | Ibsrela |
| Solventum Corporation | $14.66 | 2025 | Activ.A.C. |
| Tersera Therapeutics LLC | $14.15 | 2025 | Xermelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riley Larner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.